Erb-B2 receptor tyrosine kinase 2 mRNA (ERBB2 mRNA)

ERBB2 mRNA serves as the primary transcript for the Erb-B2 receptor tyrosine kinase 2 (HER2) protein, a critical member of the epidermal growth factor receptor family. In healthy cells, it regulates essential processes such as cell growth, differentiation, and survival through the translation of the HER2 receptor [1.2.1, 1.2.2]. However, in various malignancies, particularly breast and gastric cancers, ERBB2 mRNA is frequently overexpressed due to gene amplification, leading to an abundance of HER2 protein that drives uncontrolled cell proliferation and tumor progression [1.2.2, 1.5.1]. As a therapeutic target, ERBB2 mRNA is approached using nucleic acid-based technologies like antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which aim to silence the gene at the pre-translational level [1.3.1, 1.4.1]. These modalities offer a way to bypass resistance mechanisms associated with traditional protein-targeting therapies like monoclonal antibodies or tyrosine kinase inhibitors [1.4.2, 1.4.4]. Clinical and preclinical efforts, such as those by UTR Therapeutics, are exploring mRNA-targeting antagonists to provide more precise and potent inhibition of the HER2 pathway [1.1.1]. Monitoring ERBB2 mRNA levels also serves as a vital biomarker for predicting treatment response and patient prognosis [1.1.2, 1.5.2].

Other names

HER2 mRNANEU mRNACD340 mRNAHuman epidermal growth factor receptor 2 mRNAv-erb-b2 erythroblastic leukemia viral oncogene homolog 2 mRNA

Drugs targeting ERBB2 mRNA primarily function through antisense inhibition or RNA interference. Antisense oligonucleotides (ASOs) bind to the target mRNA via Watson-Crick base pairing, either physically blocking the translation machinery or inducing RNase H-mediated degradation of the mRNA strand [1.3.2, 1.3.4]. Small interfering RNAs (siRNAs) utilize the RNA-induced silencing complex (RISC) to direct the sequence-specific cleavage and subsequent degradation of the ERBB2 transcript [1.4.1, 1.4.5]. These mechanisms effectively reduce the production of the HER2 protein, thereby inhibiting downstream oncogenic signaling pathways such as PI3K/AKT and RAS/MAPK [1.4.2, 1.5.3].